Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will speak at two virtual investor conferences on September 17, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will speak at two virtual investor conferences on September 17, 2020. The events are the Morgan Stanley 18th Annual Global Healthcare Conference at 8:45 a.m. ET and the Cantor Fitzgerald Virtual Global Healthcare Conference at 10:00 a.m. ET. Both presentations will be webcast live on Zentalis' website. The company focuses on developing small molecule therapeutics targeting cancer pathways, with a promising pipeline including ZN-c5 for breast cancer and other inhibitors.
Details
News Market Reaction – ZNTL
The recorded move for ZNTL in the trading session of this news was -2.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.
Presentation Details:
Event: Morgan Stanley 18th Annual Global Healthcare Conference
Date: Thursday, September 17, 2020
Time: 8:45 a.m. ET
Event: Cantor Fitzgerald Virtual Global Healthcare Conference
Date: Thursday, September 17, 2020
Time: 10:00 a.m. ET
Live webcasts from the Morgan Stanley and Cantor fireside chats will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.
About Zentalis
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Investor Contact:
Thomas Hoffmann
Solebury Trout
1.646.378.2931
thoffmann@soleburytrout.com
Media Contact:
Julia Deutsch
Solebury Trout
1.646.378.2967
jdeutsch@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.